VALN Valneva SE
$5.57▲ +2.96%
Healthcare
Other
Volume 16.1K
Avg Volume (10D) 26.6K
Key Metrics & Fundamentals
Market Cap
$528.17M
P/E Ratio
–
Div Yield
0.00%
52W Range
4.75 - 12.18
% vs 50 MA
-10.98%
% vs 200 MA
-19.13%
RSI-14
44.2
MACD Histogram
-0.0100
Beta (1Y vs SPY)
0.58
Free Cash Flow
-$13.77M
Gross Rev
$34.94M
Gross Profit
$1.60M
EBITDA
-$26.51M
COGS
$33.34M
Operating Exp
$27.77M
Operating Income
-$26.17M
EBIT
-$26.17M
Pretax Income
-$31.77M
Net Income
-$31.20M
Price & Volume History
Loading chart…
Recent News
MHRA revokes approval for Valneva’s Ixchiq due to safety frailties
Pharmaceutical Technology · Oct 21, 2026 6:08 AM ET
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
GlobeNewswire · Oct 14, 2026 11:45 AM ET
Valneva Shares Fall as UK Withdraws Approval for Ixchiq Chikungunya Vaccine
InvestorsHub · Oct 8, 2026 6:09 AM ET
Valneva Says UK Revokes Chikungunya Virus Vaccine's Marketing Authorization; Shares Down Pre-Bell
MT Newswires · Oct 8, 2026 5:23 AM ET
VALN Stock Plunges 7% After-Hours As UK Revokes Valneva’s IXCHIQ Authorization In Latest Market Setback
Stocktwits · Oct 7, 2026 5:09 PM ET
Valneva ADRs fall as UK revokes IXCHIQ marketing authorization
Investing.com · Oct 7, 2026 4:39 PM ET
Valneva Provides Update on IXCHIQ® in the United Kingdom
GlobeNewswire · Oct 7, 2026 4:00 PM ET
Declaration of shares and voting rights - Status as of September 30, 2026
GlobeNewswire · Oct 5, 2026 12:00 PM ET
Could a New Vaccine Formula XFG Give Pfizer (PFE) and BioNTech (BNTX) a Post-Pandemic Revenue Boost?
Insider Monkey · Sep 24, 2026 4:27 PM ET
Pfizer (PFE), Valneva (VALN) Lyme Vaccine Moves to EMA Review Despite Phase 3 Caveat
Insider Monkey · Sep 15, 2026 12:21 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See VALN's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.